menu
    • menu
    [{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Insert","sponsorNew":"Biophta \/ UI Investissement","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ UI Investissement"},{"orgOrder":0,"company":"Biophta","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Biophta","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Biophta \/ HTL Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Biophta \/ HTL Biotechnology"}]

    Find Clinical Drug Pipeline Developments & Deals by Biophta

    Menu

    Biophta

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biophta

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biophta

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : UI Investissement

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BIOPHTA Raises €6.5M For Eye Disease Therapy Clinical Transition

                            Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                            Brand Name : BO-001

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : UI Investissement

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biophta

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biophta

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : HTL Biotechnology

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases

                            Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                            Brand Name : BO-001

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : HTL Biotechnology

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth